Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

International Journal of Geriatric Psychiatry

Volumn 26, Issue 5, 2011, Pages 483-494

  Nagy, Balázs ^a   Brennan, Alan ^a   Brandtmüller, Ágnes ^a   Thomas, Simu K ^b   Sullivan, Sean D ^c   Akehurst, Ron ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; Cost effectiveness; NHS; Rivastigmine; Transdermal

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HUMAN; MINI MENTAL STATE EXAMINATION; QUALITY ADJUSTED LIFE YEAR; SOCIAL CARE; UNITED KINGDOM;

ALZHEIMER DISEASE; BRIEF PSYCHIATRIC RATING SCALE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HUMANS; INSTITUTIONALIZATION; MALE; MODELS, ECONOMIC; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; SOCIAL SUPPORT; TRANSDERMAL PATCH;

EID: 79953241814     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2551     Document Type: Article

References (47)

1. Bavazzano A, Magnolfi S, Calvani D, et al. 1998. Functional evaluation of Alzheimer patients during clinical trials: a review. Arch Gerontol Geriatr 26(Suppl 1): 27-32.
2. Bell C, Araki S, Neumann P. 2001. The association between caregiver burden and caregiver health-related quality of life in Alzheimer disease. Alzheimer Dis Assoc Disord 15: 129-136. (Pubitemid 32807937)
3. Bowie P, Branton T, Holmes J. 1999. Should the Mini Mental State Examination be used to monitor dementia treatments? Lancet 354: 1527-1528.
4. Brazier J. 2001. Quality of Life evidence for patients with Alzheimer's disease, University of Sheffield, School of Health and Related Research.
5. Bullock R, Touchon J, Bergman H, et al. 2005. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21: 1317-1327. (Pubitemid 41140736)
6. Corey-Bloom J, Anand R, Veach J. 1998. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1: 55-65. (Pubitemid 28323228)
7. Cummings JL, Frank JC, Cherry D, et al. 2002. Guidelines for managing Alzheimer's disease: Part I. Assessment. Am Fam Physician 65: 2263-2272. (Pubitemid 34603057)
8. Curtis L. 2008. Unit Costs of Health and Social Care 2008. Personal Social Services Research Unit, University of Kent: Canterbury.
9. Curtis L, Netten A. 2006. Unit Costs of Health and Social Care 2006. Personal Social Services Research Unit, University of Kent: Canterbury.
10. Desai AK, Grossberg GT, Sheth DN. 2004. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs 18: 853-875. (Pubitemid 39612016)
11. European Medicines Agency. 2008. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. Rep. Doc. Ref. CPMP/EWP/553/95 Rev. 1.
12. Fenn P, Gray A. 1999. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach. Pharmacoeconomics 16: 165-174. (Pubitemid 29450604)
13. Ferri CP, Prince M, Brayne C, et al. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117. (Pubitemid 41797645)
14. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
15. Furlong W, Feeney D. 1998. Multiplicative multi-attribute utility function for the Health Utilities Index Mark 3 (HUI 3) system: A technical report. McMaster University Centre for Health Economics and Policy Analysis. Working Paper no. 98-11.
16. Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. 2002. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 20: 629-637.
17. Green C. 2007. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 25: 735-750. (Pubitemid 47481639)
18. Grossberg G, Sadowsky C, Förstl H, et al. 2009. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 23: 158-164.
19. Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R. 2009. Predicting time to nursing home placement based on activities of daily living scores - a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. J Med Econ 12: 98-103.
20. Hauber AB, Gnanasakthy A, Mauskopf JA. 2000a. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 22: 439-451. (Pubitemid 30304795)
21. Hauber AB, Gnanasakthy A, Snyder EH, et al. 2000b. Potential savings in the cost of caring for Alzheimer's disease - treatment with rivastigmine. Pharmacoeconomics 17: 351-360. (Pubitemid 30236170)
22. Ikeda S, Yamada Y, Ikegami N. 2002. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 13: 33-39. (Pubitemid 33153186)
23. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. 1999. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 21: 1230-1240. (Pubitemid 29380477)
24. Knapp M, Prince M. 2007. Dementia UK: A Report to the Alzheimer's Society on the Prevalence and Economic Cost of Dementia in the UK Produced by King's College London and London School of Economics. Alzheimer's Society: London.
25. Loveman E, Green C, Kirby J, et al. 2006. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 10 (iii-iv, ix-xi): 1-160.
26. Martin DC, Miller JK, Kapoor W, Aerna VC, Boller F. 1987. A controlled study of survival with dementia. Arch Neurol 44: 1122-1126. (Pubitemid 17154982)
27. McNamee P, Bond J, Buck D. 2001. Costs of dementia in England and Wales in the 21st century. Br J Psychiatr 179: 261-266. (Pubitemid 32844289)
28. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. 2000. Modelling Mini Mental State Examination changes in Alzheimer's disease. Stat Med 19: 1607-1616. (Pubitemid 30346250)
29. Mercier F, Lefèvre G, Huang HL, et al. 2007. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 23: 3199-3204.
30. Migliaccio-Walle K, Getsios D, Caro JJ, et al. 2003. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 25: 1806-1825. (Pubitemid 36801950)
31. Netten A, Darton R, Bebbington A, et al. 2001. Residential and nursing home care of elderly people with cognitive impairment: prevalence, mortality and costs. Aging Ment Health 5: 14-22. (Pubitemid 32220694)
32. Neumann PJ, Hermann RC, Kuntz KM, et al. 1999. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52: 1138-1145. (Pubitemid 29177912)
33. NICE. 2004. Guide to the Methods of Technology Appraisal. National Institute for Clinical Excellence: London.
34. NICE. 2008. Guide to the Methods of Technology Appraisal. National Institute for Clinical Excellence: London.
35. NICE. 2006a. Dementia - Supporting People with Dementia and their Carers in Health and Social Care - NICE Clinical Guideline 42. National Institute for Clinical Excellence: London.
36. NICE. 2006b. Donepezil, Galantamine, Rivastigmine (Review) and Memantine for the Treatment of Alzheimer's Disease - Final Appraisal Determination. National Institute for Clinical Excellence: London.
37. NICE. 2009. Donepezil, Galantamine, Rivastigmine (Review) and Memantine for the Treatment of Alzheimer's Disease (Amended). National Institute for Clinical Excellence: London.
38. O'Brien BJ, Goeree R, Hux M, et al. 1999. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 47: 570-578. (Pubitemid 29215586)
39. Rösler M, Anand R, Cicin-Sain A, et al. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 318: 633-638.
40. Rozsa S. 2007. The Psychometric Properties of ADCS - Activities of Daily Living Inventory and Comparison of Different ADL Scores. Department of Personality and Health Psychology, Loránd Eötvös University: Budapest, Hungary.
41. Stewart A. 1997. Costs of care for people with dementia aged 75 and over. 1303/2, Personal Social Services Research Unit (PSSRU).
42. Stewart A, Phillips R, Dempsey G. 1998. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatr 13: 445-453. (Pubitemid 28370550)
43. Townsend P. 1979. Poverty in the United Kingdom, a Survey of Household Resources and Standards of Living. Penguin Books and Allen Lane. London.
44. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. 2003. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21: 327-340. (Pubitemid 36403437)
45. Winblad B, Cummings J, Andreasen N, et al. 2007a. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatr 22: 456-467. (Pubitemid 46831690)
46. Winblad B, Kawata AK, Beusterien KM, et al. 2007b. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatr 22: 485-491. (Pubitemid 46831693)
47. Wolstenholme J, Fenn P, Gray A, et al. 2002. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatr 181: 36-42. (Pubitemid 34717836)